RESEARCH ARTICLE

Economic evaluations considering costs and outcomes of diabetic foot ulcer infections: A systematic review

Taylor-Jade Woods, Fisaha Tesfay, Peter Speck, Billingsley Kaambwa

1 College of Medicine and Public Health, Flinders University, Bedford Park, South Australia, 2 College of Science and Engineering, Flinders University, Bedford Park, South Australia

* These authors contributed equally to this work.
* wood0302@flinders.edu.au

Abstract

Background

Diabetic foot ulcer (DFU) is a severe complication of diabetes and particularly susceptible to infection. DFU infection intervention efficacy is declining due to antimicrobial resistance and a systematic review of economic evaluations considering their economic feasibility is timely and required.

Aim

To obtain and critically appraise all available full economic evaluations jointly considering costs and outcomes of infected DFUs.

Methods

A literature search was conducted across MedLine, CINAHL, Scopus and Cochrane Database seeking evaluations published from inception to 2019 using specific key concepts. Eligibility criteria were defined to guide study selection. Articles were identified by screening of titles and abstracts, followed by a full-text review before inclusion. We identified 352 papers that report economic analysis of the costs and outcomes of interventions aimed at diabetic foot ulcer infections. Key characteristics of eligible economic evaluations were extracted, and their quality assessed against the Consolidated Health Economic Evaluation Reporting Standards (CHEERS) checklist.

Results

542 records were screened and 39 full-texts assessed for eligibility. A total of 19 papers were included in the final analysis. All studies except one identified cost-saving or cost-effective interventions. The evaluations included in the final analysis were so heterogeneous that comparison of them was not possible. All studies were of “excellent”, “very good” or “good” quality when assessed against the CHEERS checklist.
Conclusions

Consistent identification of cost-effective and cost-saving interventions may help to reduce the DFU healthcare burden. Future research should involve clinical implementation of interventions with parallel economic evaluation rather than model-based evaluations.

Introduction

Diabetic foot ulcers (DFU) are a common and severe complication of diabetes mellitus characterised by a deep tissue lesion. [1] Factors underlying the development of DFU are peripheral sensory neuropathy, foot deformity, minor foot trauma and peripheral arterial disease. [2] It is estimated that the annual incidence of DFU is 2–4% [3, 4] in developed countries with only two-thirds of cases healing within 12 months. [5] A significant consequence for those DFUs which do not heal is infection which has an incidence of 40.1%. [6] DFU infection is a well-recognised risk-factor for lower extremity amputation which occurs in 8% [5] of cases and carries a 5-year mortality of 74%. [7]

Not only is DFU a source of significant patient suffering, it also brings significant costs to the individual and healthcare system. The cost burden of DFU requires 6 days to 5.7 years of patient income to cover treatment cost with variation based on setting and treatment strategy. [8] The annual cost of DFU treatment is significantly greater than non-diabetic foot ulcer treatment, estimated at $1.38 billion versus $0.13 billion. [9] DFU infection places an additional burden on the healthcare system. Cost per admission among patients with DFU infection versus without was significantly higher in those with infected DFU ($11,290 versus $8,145). [9]

Cost-effective DFU interventions have been identified in previous systematic reviews of economic evaluations, [10–13] however these reviews do not focus on those evaluations where infection is part of the clinical presentation of the DFU or model pathway. Given the high prevalence of infection in DFU and the accompanying economic burden, it is essential to illuminate potentially cost-saving or cost-effective interventions to reduce the burden of DFU infection. We therefore seek to obtain all available economic evaluations that jointly consider the costs and outcomes of DFU with infection considered as part of the clinical situation and critically appraise this literature.

Methods

Search strategy

A literature search was conducted using MedLine, CINAHL, Scopus and Cochrane Databases seeking articles published in English from inception to 2020. Terms including diabetic foot, economic evaluation and infection were used as Medical Subject Headings (MeSH) and text-words to capture the outcomes of interest. The MedLine search strategy, adapted for use in other databases, is presented in Table 1. The last database search was 31 Jan 2020.

Study selection

Studies were included if:

1. they compared costs and outcomes in conjunction as part of a stand-alone economic evaluation or alongside a clinical trial or other study design types such as model-based economic evaluations,

2. the study population was exclusively 18 years and over,
3. the study population was diabetic with an infected foot ulcer,

4. they were published in the English language in peer reviewed journals between inception and 2020.

Studies were excluded if:

1. costs and outcomes were not considered and/or compared,

2. study population was not over the age of 18,

3. they were theory papers, letters, editorials, reviews, theses, or dissertations and studies where full texts could not be obtained.

This systematic review was conducted according to the Preferred Reporting Items of Systematic Reviews and Meta-Analyses (PRISMA) guidelines and the checklist is provided as supporting information (S1 Checklist). [14] Articles were identified by screening titles and abstracts, followed by assessment of full-texts for eligibility.

Data extraction and quality assessment

Key characteristics of the economic evaluations were identified and extracted including study design and perspective, study population, intervention and comparator(s), time horizon and discount rate, methods or model used, costs included, reporting of costs, outcomes measuring health benefit and cost-effectiveness and overall economic evaluation result.

Quality assessment of the reporting of identified studies was performed according to the 24-item Consolidated Health Economic Evaluation Reporting Standards (CHEERS) checklist. [15] Two reviewers independently assessed articles against the criteria, calculating a score out of 24. Each item was assigned one-point, partial marks were awarded if the study did not completely fulfill the criteria, for example if perspective or discount rate choices were not

| Searches |
|-----------------|
| 1 Diabetic Foot/ |
| 2 Foot Ulcer/ and (diabetes mellitus/ or diabetes mellitus, type 1/ or diabetes mellitus, type 2/) |
| 3 (diabet* adj3 (foot or feet or wound* or ulcer* or lesion* or lower limb* or lower extremi*)).tw,kf. |

4 or/1-3 economics/ or "costs and cost analysis"/ or "cost allocation"/ or cost-benefit analysis/ or "cost control"/ or "cost of illness"/ or health care costs/ or direct service costs/ or hospital costs/ or health expenditures/ or economics, hospital/ or hospital charges/ or economics, medical/ or fees, medical/ or economics, nursing/ or economics, pharmaceutical/ |

6 quality-adjusted life years/ |

7 (QALY or ((cost* or economic*) adj3 (minimi* or utilit* or evaluat* or review* or outcome* or analys* or effect* or benefit))).tw,kf. |

8 (cost* or economic*).ti. |

9 or/5-8 infection/ or community-acquired infections/ or cross infection/ or opportunistic infections/ or superinfection/ or staphylococcal skin infections/ or soft tissue infections/ or suppuration/ or abscess/ or wound infection/ or surgical wound infection/ |

11 Gangrene/ |

12 (infection* or abscess* or gangren*).tw,kf. |

13 or/10-12 4 and 9 and 13 |

15 Limit 14 to English language

https://doi.org/10.1371/journal.pone.0232395.t001
explained. Any differences in marks awarded were discussed by reviewers to reach consensus. Calculation of a percentage score was performed. Given the absence of a largely accepted method for quality appraisal, set categories were based on published literature. [16–19] Studies scoring 85% or higher were of “excellent” quality, studies scoring between 70-<85% of “very good” quality, studies scoring 55-<70% were rated to have “good” quality and studies scoring below 55% were classified as “poor” quality.

Results

Study selection

PRISMA guidelines [14] were followed in the study selection process (Fig 1). Database searches identified 527 studies and an additional 63 records were identified through screening of referencing lists; 93 duplicates were removed. Titles and abstracts of 542 articles were screened for eligibility; 503 did not meet the criteria. During this stage, a second reviewer independently assessed 20% of these articles for eligibility and interrater agreement was calculated using Cohen’s kappa statistic. [20] Thirty-nine full-texts were assessed for eligibility. Two papers did not consider DFU infection, [21, 22] three did not report participant age, [23–25] one did not consider DFU, [26] two were review papers [27, 28] and one was not published in a peer-reviewed journal. [29] Eleven papers did not consider

Fig 1. Preferred Reporting Items of Systematic Reviews and Meta-Analyses (PRISMA) flow diagram showing study selection process. DFU: diabetic foot ulcer.

https://doi.org/10.1371/journal.pone.0232395.g001
and/or compare costs and outcomes as in a full economic evaluation. [30–40] Study eligibility agreement between both reviewers was ‘almost perfect’ with a kappa statistic of 0.83. Nineteen studies were included in the final analysis. All papers [41–59] were full economic evaluations considering and comparing the costs and benefits of interventions against comparators.

Economic evaluation characteristics

Study setting and cohort. Study settings were diverse and accounted for South America, [41, 55] Australia, [42] Canada, [43] China, [59] Europe [47, 49, 51–54, 56] and North America [44–46, 48, 50, 57, 58] (Table 2). Patients across all age groups 18 years and over were captured. Four cohorts were derived from clinical trials [44, 50, 57, 58] and some studies focused on moderate to severe, [48, 55–57] or non-healing [44] DFUs only. DFU infection was a part of the clinical presentation or model pathway in all studies.

Study perspectives. The economic perspective taken by each study determines the cost and benefits included. [17] The societal perspective was taken by Cárdenas et al. [41] and Redekop et al. [54] The perspective of the healthcare system was taken in six studies [42, 43, 50, 55, 57, 59] and the payers perspective was taken in five [45, 46, 49, 56, 58] (Table 2). Both the societal and payers perspectives were taken by Guo et al. [48] Perspective was not reported in five studies, [44, 47, 51–53] however Ortegon et al. [51] discussed some results from the policy and clinical perspective.

Intervention and comparator. A multitude of interventions were used to manage DFUs, typically antimicrobials or wound care strategies, reflecting components of the standard treatment of DFUs [2, 60] (Table 2). Most economic evaluations assessed adjuncts to standard wound care strategies. [41, 47, 54–56] Two studies assessed becaplermin gel plus good wound care (GWC) [52, 58] and two studies assessed hyperbaric oxygen therapy (HBOT). [43, 48] The overall wound care strategy was compared in three studies, each comparing what was locally considered as standard versus optimal wound care. [42, 53, 59] Wound dressings were assessed in four.

Time horizon. Time horizons should be specified and cover the provision of the intervention and tracking of costs and consequences/benefits. Ideally, they should reflect actual clinical practice. One-year [41, 45, 54, 58] and five-year time horizons were most common. [42, 44, 53, 55, 56, 59] The longest time horizon was 12-years by Chuck et al. [43] Short time horizons were taken by Gilligan et al. [46] and Guest et al. [47] of three and four months respectively. Two time horizons were taken in two papers, Tesar et al. [56] used 5- and 10-year time horizons and Lobmann et al. [49] used 20-week and 100-week time horizons. Persson et al. time horizon was between one and two years. [52]

Four studies did not explicitly report the time horizon. [48, 50, 51, 57] In McKinnon et al., [50] time horizon was ambiguous, reported as being from the beginning of study-drug commencement to the completion of study-drug or secondary treatment following clinical failure. Overall, reported time horizons ranged from 12 weeks to 12 years.

Discount rates. Discount rates allow economic evaluations to account for changes in the value of money over time. Four studies did not report a discount rate. [43, 44, 49, 57] Three studies used a 3% discount rate, however none of them justified this choice. [48, 51, 53] Four studies used a 5% discount. [42, 52, 55, 59] All studies with a time horizon of one year of less did not discount costs. [41, 45–47, 50, 54, 58]

Study designs and models used. Eleven studies were CEAs, [41–43, 45, 47, 49, 52, 54, 55, 58, 59] another five were CUAs, [44, 48, 51, 53, 56] while three studies found the interventions were equally efficacious, therefore costs were directly compared as in a CMA. [46, 50, 57]
| Authors, Country, Year | Study design, study perspective | Study population | Intervention, comparator | Time horizon, discount rate | Methods or model | Costs included | Reporting of costs | Measures of health benefits and cost-effectiveness | ICER or Overall economic evaluation result |
|------------------------|--------------------------------|------------------|--------------------------|-----------------------------|-----------------|---------------|------------------|-----------------------------------------------|-----------------------------------------------|
| Cárdenas et al, [41] Peru, 2015 | CEA, societal perspective. | Peruvian 18–79 year olds, type 2 diabetics. | Sub-optimal care versus SWC; sub-optimal care versus SWC plus foot temperature monitoring; SWC versus SWC plus foot temperature monitoring. | One year, no discount. | Decision tree model. | Procedural intervention, personnel, medical supplies, examinations and medication. | Indirect cost of premature death. | PEN converted to USD based on 2012 exchange rate of 2.64 PEN per USD. | Cost per death averted. |
| Cheng et al, [42] Australia, 2017 | CEA, health system perspective. | Diabetic patients at high risk of DFU, age groups 35–54, 55–74, 75+ years. | SWC versus optimal care. | 5 years, 5% discount. | Markov model. | Costs associated with each health state and transition, GP consultation, podiatrist consultation. | 2013 AUD. | QALYs. |
| Chuck et al, [43] Canada, 2008 | CEA, Ministry of Health perspective. | Canadian 65-year old cohort with DFU, inpatients and outpatients. | Adjunctive HBOT plus SWC versus SWC alone. | 12 years, no discount reported. | Decision model based on Guo et al. applied in Canadian context. | Annual wound care costs adjusted for health states. | 2004 CAD. | Numbers of LEAs, number of healed wounds, number of unhealed wounds. |
| Dougherty et al, [44] US, 2008 | CUA, perspective not reported. | Non-healing DFU patients. | PRP gel versus alternative therapies. Control was saline dressing. | 5 years, no discount reported. | Decision analysis model. | Costs per treatment modality, weekly costs of an unhealed ulcer and severe infection. Monthly cost of uncomplicated ulcer. Costs of amputation. | 2006 USD. | Clinical outcomes costs and QALYs associated with PRP gel versus alternative therapies. |
| Flack et al, [45] US, 2008 | CEA, payer’s perspective. | DFU patients aged 50–65 years. | VAC therapy versus advanced and traditional dressings. | One year, no discount. | Markov model. | Inpatient or outpatient care, professional and pharmacy services, other costs and material dressing. | 2006 USD. | Wound healing, incremental cost per QALY |
| Gilligan et al, [46] US, 2015 | CMA, third-party payer perspective from Centres for Medicare and Medicaid Services. | Type 1 and 2 diabetics with DFU extending into epidermis. | ECM versus HFDS. | 12 weeks, no discount. | Two-state Markov model. | Direct medical costs of care, not itemised. | 2014 USD | Cost per wound closure. |

(Continued)
| Authors, Country, Year | Study design, study perspective | Study population | Intervention, comparator | Time horizon, discount rate | Methods or model | Costs included | Reporting of costs | Measures of health benefits and cost-effectiveness | ICER or Overall economic evaluation result |
|------------------------|---------------------------------|------------------|--------------------------|-----------------------------|-----------------|---------------|-------------------|------------------------------------------------|----------------------------------|
| Guest et al, [47] UK, 2018 | CEA, perspective not reported. | 130 DFU patients. | SWC alone versus SWC plus a collagen-containing dressing. | Four months, no discount. | Decision model. | Wound care (dressing costs, bandages). | Patient management under National Health Services estimated at 2015/16 prices in GBP. | QALYs gained after 4 months. | Collagen-containing dressing plus SWC dominant versus SWC alone. |
| Guo et al, [48] US, 2003 | CUA, payer's and societal perspectives. | 1,000 60-year-old severe DFU patients (Wagner grade 3 and above). | SWC plus HBOT versus SWC alone. | Time horizon 1, 5 and 12-years. 3% discount. | Decision tree model. | HBOT technical and physician fees. Amputation surgery, inpatient care, rehabilitation, first-year outpatient visits. | 2001 USD. LEAs averted, QALYs gained. | Adjunct HBOT cost-effective. ICER at years 1, 5 and 12 were $27,310, $5,166, and $2,255 respectively. |
| Lobmann et al, [49] Germany, 2018 | CEA, German statutory health insurance. | 240 DFU patients at mean age of 64 years. | TLC-NOSF dressing versus control dressing. | 20 weeks, 100 weeks; discount not reported. | Markov model. | Nursing, medical consultation/physician fees, wound care products, inpatient stay and pharmacotherapy. | Euro, currency year not reported. | Wound healing rate. | TLC-NOSF dominant versus control dressing. |
| McKinnon et al, [50] US, 1997 | CMA, hospital perspective. | DFU patients enrolled in a completed randomised double-blind trial. | Ampicillin/sulbactam versus imipenem/cilastatin. | Time horizon not explicit, intervention duration or until clinical failure. No discount. | Decision model. | Antibiotic acquisition, preparation and administration, hospital bed. Treatment after clinical failure. Treatment of adverse events. | 1994 USD. | Treatment success, failure, indeterminate. | Success rate identical for both interventions, ampicillin/sulbactam cost-saving ($14,084 vs. $17,008). |
| Ortegon et al, [51] Netherlands, 2004 | CUA, no specific perspective. | 10,000 newly-diagnosed type 2 diabetics in the Netherlands. | IGC alone, GFC alone, IGC plus GFC. | Time horizon not specified, 3% discount. | Risk-based Markov model. | Labour, medication, laboratory costs, materials and procedure costs. | 1999 USD. | QALYs. | IGC plus GFC <25,000 per QALY. IGC alone was $32,057 per QALY. GFC alone ranged from $12,169 to $200,100. |
| Persson et al, [52] Sweden, 2000 | CEA, perspective not reported. | Neuropathic DFU patients treated with GWC. | Becaplermin gel plus GWC versus GWC alone. | 12, 18 and 24 months. Costs are discounted at 5% per year. | Markov simulation model. | Topical treatment, antibiotics, outpatient and inpatient care, social services/home care, amputation and prosthesis. | 1999 USD. | Ulcers healed or healing time. | Becaplermin plus GWC dominant versus GWC alone. |
| Authors, Country, Year         | Study design, study perspective | Study population | Intervention, comparator | Time horizon, discount rate | Methods or model | Costs included | Reporting of costs | Measures of health benefits and cost-effectiveness | ICER or Overall economic evaluation result |
|-------------------------------|---------------------------------|------------------|--------------------------|-----------------------------|-------------------|----------------|-------------------|---------------------------------------------------|------------------------------------------|
| Redekop et al, [54] Netherlands, 2003 | CEA, societal perspective. | Patients enrolled in the Apligraf Diabetic Foot Ulcer Study (ADFUS). | Apligraf plus GWC versus GWC alone. | 12 months, no discount. | Markov-based simulation model. | Apligraf costs, outpatient clinic visits, podiatrist visits, GP visits, homecare, hospital days, debridement, antibacterial, diagnostic tests, footwear and dressings. | 1999 Euro. | Incremental cost per ulcer-free month gained and per amputation avoided. | Apligraf plus GWC dominant versus GWC alone. |
| Romero Prada et al, [55] Colombia, 2018 | CEA, Colombian health system perspective. | Patients diagnosed with Wagner’s grade 3 or 4 DFU. | rhEGF plus SWC versus SWC alone. | 5-year horizon, 5% discount. | Markov model. | Direct costs of health resources, procedures, prosthesis, rehabilitation and inputs. | 2016 and 2017 USD. | QALYs. | rhEGF cost effective, ICER US$13,428. |
| Ragnarson et al, [53] Sweden, 2001 | CUA, perspective not reported. | 10,000 diabetics over the age of 24. | Optimal prevention versus current prevention strategies in Sweden. | 5 years, 3% discount. | Markov model. | Ulcer and amputation prevention, amputations, home care and social services, costs of remaining in or transitioning between health states, prostheses, inpatient and outpatient care. | Costs inflated to 1998 SEK, converted to Euro. | QALYs. | Optimal prevention was dominated in group 1. Optimal prevention dominant in all risk groups except group 3 in age groups 24–69 (€5087/QALY) and 70–84 (€4045/QALY). |
| Tesar et al, [56] Slovakia, 2017 | CUA, perspective of health care payers. | Not reported. | Heberprot-P plus GWC versus GWC alone. | 5- and 10-year time horizons, 5% discount. | Markov model. | Heberprot-P treatment cost. No other cost inclusions reported. | 2011 Euro. | QALYs. | Heberprot-P plus GWC dominated by GWC alone. |
| Tice et al, [57] US, 2007 | CMA, hospital perspective. | Adult diabetics previously enrolled in clinical trial with moderate to severe foot infections. | Intravenous ertapenem versus piperacillin plus tazobactam. | Time horizon not reported. Discount not reported. | Cost comparison between antibiotic regimens. | Drug acquisition, preparation, labour costs, consumable costs. Supply costs discounted by 40%. | 2005 USD. | N/A. | Ertapenem cost saving versus piperacillin/tazobactam ($355.55 versus $502.76). |
| Waycaster et al, [58] US, 2016 | CEA, third-party payer perspective. | DFU patients enrolled in one of three phase III clinical trials. | Becaplermin gel plus GWC versus GWC. | 1 year, no discount. | WSA reduction rate used to predict costs and outcomes of wound healing. | Becaplermin gel, patient evaluation and management, procedure cost, ankle brachial index test. | 2013 USD. | Cost per 1cm² reduction in WSA. | Becaplermin plus GWC dominant versus GWC alone. |
Two studies did not use an economic model to simulate the impact of interventions on DFU. \cite{57, 58} Tice et al. performed a direct cost comparison as each intervention was assumed to be equally efficacious. \cite{57} Waycaster et al. used wound surface area reduction rates to predict costs associated with DFU healing. \cite{58} Seven studies used a decision-tree analytical model. \cite{41, 43, 44, 47, 48, 50, 59} The Markov model was the most common choice and was used in ten studies. \cite{42, 45, 46, 49, 51–56}

Costs included. There was variation between cost inclusions in each study depending on setting, perspective and interventions investigated. Some studies kept a narrow scope of direct costs associated with the intervention \cite{47, 56, 57} or ulcer state, \cite{44} but most studies had a broad scope of inclusions that captured DFU intervention, rehabilitation and patient management. \cite{41, 48, 49, 52–55, 58, 59} Indirect costs were only itemised in one study. \cite{41}

Overall economic evaluation results. All evaluations except one concluded the intervention assessed was cost-effective or cost saving. This means all interventions provided more health benefit at a lower incremental cost most of the time. All CMAs showed the intervention achieved equal health benefit at lower costs versus the comparator.

While the evaluations are incomparable due to heterogeneous methods and analyses, the intervention dominated the comparator in nine studies by providing greater health benefits at lower cost. \cite{42–45, 47, 49, 52, 54, 59} The intervention was dominated by the comparator in one study due to the unit cost of the adjunct. \cite{56} Six studies found the intervention to be cost-effective \cite{41, 48, 51, 53, 55, 58} and three found the intervention was cost saving as the health benefits were equivalent. \cite{46, 50, 57} Ragnarson et al. \cite{53} found the intervention was dominant or cost-effective for higher risk patients in all age groups, but was dominated by the comparator in the lowest risk group.

Adjuncts were dominant or cost-effective interventions in nine of ten papers. McKinnon et al. \cite{50} and Tice et al. \cite{57} directly compared two antibiotics, one of which was considered conventional care, but neither study used the same antibiotics.

https://doi.org/10.1371/journal.pone.0232395.t002

---

### Table 2. (Continued)

| Authors, Country, Year | Study design, study perspective | Study population | Intervention, comparator | Time horizon, discount rate | Methods or model | Costs included | Reporting of costs | Measures of health benefits and cost-effectiveness | ICER or Overall economic evaluation result |
|------------------------|---------------------------------|------------------|--------------------------|----------------------------|-----------------|---------------|------------------|-----------------------------------------------|------------------------------------------|
| Wu, et al, [59] China, 2018 | CEA, Chinese healthcare system. | Patients with type 2 diabetes at low, moderate and high risk of DFU. | Optimal care versus SWC. | 5 years, 5% discount. | Decision-analytic model. | Direct medical costs and resource utilisation. | 2016 USD. | QALYs. | Optimal wound care dominant versus SWC. |
saving. In the four studies which assessed dressings, three found the intervention was dominant [44, 45, 49] and one found the intervention was cost-saving. [46] Three papers compared standard wound care to optimal wound care strategies. [42, 53, 59] Cheng et al. [42] and Wu et al. [59] found optimal wound care was dominant while Ragnarson et al. [53] found optimal wound care was dominant or cost-effective only in higher risk groups.

**Quality assessment of economic evaluations**

The reporting quality of each paper was assessed against the 24-item CHEERS checklist. [15] Studies were allocated one mark for each criterion met in full (represented by √), 0.5 marks if the criterion was partially met (represented by ≠) or if the criterion was not met, 0 marks (represented by ×) (Table 3). The total possible score was reduced by one point for all criteria that were not applicable (N/A) to a single study. For example, studies that were not model-based could not be assessed by criteria 15 or 16 (model justification and assumptions). Six studies were of "excellent" quality (scoring >85%). [41, 45, 49, 55, 58, 59] Nine studies were of "very good" quality (scoring 70–<85%) [42, 43, 46–48, 50, 52, 54, 56] and four studies were of "good" quality (scoring 55–<70%). [44, 51, 53, 57] The best addressed criterion was findings and limitations; conversely, the least addressed areas were study perspective, time horizons and discount rates. Many studies failed to report these and where reported, justification of their relevance was absent. Similarly, discussion of choice of outcomes was rarely related to the particular health state or intervention.

**Discussion**

Whilst the need for effective DFU interventions increases, few have been subject to economic evaluation. All interventions examined in these evaluations were cost-effective or cost-saving in a clinical situation involving DFU infection. Collectively, they suggested that short- and long-term implementation of such interventions could reduce the burden of DFU infection on healthcare systems while providing optimal patient management. Although the evaluations captured the standard care for DFUs and associated costs, other considerations were made on the issue. These included assessments of antibiotic efficacy, route and setting of administration and the overall strategies embodied in a variety of guidelines and recommendations.

Seventeen evaluations were model-based and did not implement the intervention in clinical settings. [41–56, 59] They relied on published data and literature to build a model that simulated the intervention and transitions between health states. Decision tree and Markov models were used, and model justification and assumptions were generally well-reported. Although models are widely accepted methods for informing policy-making decisions, [19] future research would benefit from implementing the interventions in a clinical setting.

Together all evaluations assessed at least one component of the DFU management strategy, with adjuncts assessed in most papers. Because the treatment of DFUs has multiple components including antimicrobials and standard wound care, it was to be expected that these economic evaluations would be too heterogeneous for comparison.

Quality assessment of studies against the CHEERS checklist [15] found all studies to be of "excellent", [41, 45, 49, 55, 58, 59] "very good" [42, 43, 46–48, 50, 52, 54, 56] and "good" [44, 51, 53, 57] quality, adding strength to the conclusions drawn in this review. Furthermore, some studies included were published before the conception of the CHEERS checklist in 2013. [15] This shows that high-quality studies with earlier publication dates conform with the guidelines crystallised in the checklist and supports the comprehensiveness of the search strategy.
Table 3. Quality assessment of publications against the Consolidated Health Economic Evaluations Reporting Standards (CHEERS) checklist.

| Authors, year | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 |
|---------------|---|---|---|---|---|---|---|---|---|
| Cardenas, et al 2015 | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
| Cheng et al 2017 | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
| Chuck et al 2008 | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
| Dougherty et al 2008 | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
| Flack, et al 2008 | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
| Gilligan et al 2015 | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
| Guest et al 2018 | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
| Guo et al 2003 | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
| Lobmann, et al 2019 | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
| McKinnon et al. 1997 | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
| Ortega et al. 2004 | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
| Persson, et al 2000 | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
| Ragnarson Tennvall et al. 2001 | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
| Redekop et al. 2003 | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
| Romero Prada, et al 2018 | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
| Tesar, et al. 2017 | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
| Tice et al. 2007 | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
| Waycaster et al. 2016 | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
| Wu, et al 2018 | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |

(Continued)
| Authors, year       | Title identified as economic evaluation | Structured abstract | Intro provides context, study question and relevance | Population | Setting and location | Study perspective | Comparators | Time horizon | Discount rate | Outcomes and relevance | Sensitivity of incremental costs or model sensitivity analysis | Heterogeneity explanation | Findings and limitations | Funding source(s) | Conflict of interest | Total % |
|---------------------|----------------------------------------|---------------------|---------------------------------------------------|------------|---------------------|------------------|-------------|--------------|---------------|----------------------|---------------------------------|--------------------------|----------------------|------------------|---------------------|--------|
| Tesar et al. 2017   | √                                       | √                   | √                                                 | √          | √                   | ×                | √           | ×          | ×              | √                   | √                             | √                       | √                    | ×                | ×               | 17.5/23 93% |
| Tice et al. 2007    | ×                                       | ×                   | ×                                                 | N/A        | √                   | ×                | N/A         | ×          | ×              | √                   | ×                             | √                       | ×                    | ×                | ×               | 19/23 82%   |
| Waycaster et al. 2016 | ×                                       | √                   | N/A                                               | √          | √                   | ×                | N/A         | ×          | ×              | √                   | ×                             | √                       | ×                    | ×                | ×               | 15.5/24 65% |
| Wu, et al 2018      | √                                       | √                   | N/A                                               | √          | √                   | ×                | √           | ×          | ×              | √                   | ×                             | √                       | ×                    | ×                | ×               | 20/23 87%   |

There are some limitations to our study. The results of this review rely exclusively upon studies published in English, which may not represent all research. Grey literature that is unpublished or published but non-commercially available was not searched due to time constraints. Full texts that could be obtained were limited to those accessible by the Flinders University library system. Although few studies were parallel evaluations to clinical trials, the majority of
studies were model-based so the results relied heavily upon simulation of intervention effects rather than clinical application.

**Conclusion**

In conclusion, economic evaluations have considered all aspects of DFU intervention, finding there is potential to select more cost-saving and cost-effective alternative to reduce the burden of DFU. Instead of model-based evaluations, future research should be directed toward actual implementation of interventions in clinical settings with economic evaluations in parallel.

**Supporting information**

S1 Checklist. Preferred Reporting Items of Systematic Reviews and Meta-Analyses (PRISMA) checklist.

(DOCX)

**Author Contributions**

Conceptualization: Taylor-Jade Woods, Peter Speck, Billingsley Kaambwa.

Data curation: Taylor-Jade Woods, Fisaha Tesfay, Peter Speck, Billingsley Kaambwa.

Formal analysis: Taylor-Jade Woods, Fisaha Tesfay, Peter Speck, Billingsley Kaambwa.

Investigation: Taylor-Jade Woods, Fisaha Tesfay, Peter Speck, Billingsley Kaambwa.

Methodology: Taylor-Jade Woods, Peter Speck, Billingsley Kaambwa.

Project administration: Taylor-Jade Woods, Peter Speck, Billingsley Kaambwa.

Resources: Peter Speck, Billingsley Kaambwa.

Supervision: Peter Speck, Billingsley Kaambwa.

Validation: Taylor-Jade Woods, Peter Speck, Billingsley Kaambwa.

Visualization: Taylor-Jade Woods, Peter Speck, Billingsley Kaambwa.

Writing – original draft: Taylor-Jade Woods.

Writing – review & editing: Taylor-Jade Woods, Peter Speck, Billingsley Kaambwa.

**References**

1. Skyler JS, Bakris GL, et al. Differentiation of diabetes by pathophysiology, natural History, and prognosis. Diabetes. 2017; 66(2):241–55. https://doi.org/10.2337/db16-0806 PMID: 27980006

2. Bakker K, Apelqvist J, et al. The 2015 IWGDF guidance documents on prevention and management of foot problems in diabetes: development of an evidence-based global consensus. Diabetes Metab Res Rev. 2016; 32(S1):2–6.

3. Boulton AJM, Vileikyte L, et al. The global burden of diabetic foot disease. Lancet. 2005; 366 (9498):1719–24. https://doi.org/10.1016/S0140-6736(05)67698-2 PMID: 16291066

4. Lin C-W, Armstrong DG, et al. Nationwide trends in the epidemiology of diabetic foot complications and lower-extremity amputation over an 8-year period. BMJ Open Diabetes Res Care. 2019; 7(1):e000795. https://doi.org/10.1136/bmjdrc-2019-000795 PMID: 31749971

5. Jeffcoate WJ, Chipchase SY, et al. Assessing the outcome of the management of diabetic foot ulcers using ulcer-related and person-related measures. Diabetes Care. 2006; 29(8):1784. https://doi.org/10.2337/dc06-0306 PMID: 16873780

6. Jia L, Parker CN, et al. Incidence and risk factors for developing infection in patients presenting with uninfected diabetic foot ulcers. PLoS One. 2017; 12(5):e0177916. https://doi.org/10.1371/journal.pone.0177916 PMID: 28545120
7. Robbins JM, Strauss G, et al. Mortality rates and diabetic foot ulcers is it time to communicate mortality risk to patients with diabetic foot ulceration? J Am Podiatr Med Assoc. 2008; 98(6):489–93. https://doi.org/10.7547/0980489 PMID: 19017860

8. Cavanagh P, Attinger C, et al. Cost of treating diabetic foot ulcers in five different countries. Diabetes Metab Res Rev. 2012; 28(S1):107–11.

9. Hicks CW, Selvarajah S, et al. Burden of infected diabetic foot ulcers on hospital admissions and costs. Ann Vasc Surg 2016; 33:149–58. https://doi.org/10.1016/j.avsg.2015.11.025 PMID: 26907372

10. Health Quality Ontario. Hyperbaric oxygen therapy for the treatment of diabetic foot ulcers: a health technology assessment. Ont Health Technol Assess Ser 2017; 17(5):1–142. PMID: 28572866

11. Health Quality Ontario. Fiberglass total contact casting, removable cast walkers, and irremovable cast walkers to treat diabetic neurotrophic foot ulcers: a health technology assessment. Ont Health Technol Assess Ser 2017; 17(12):1–124. PMID: 28989556

12. Liu S, He C-z, et al. Evaluation of negative-pressure wound therapy for patients with diabetic foot ulcers: systematic review and meta-analysis. Ther Clin Risk Manag. 2017; 13:533–44. https://doi.org/10.2147/TCRM.S131193 PMID: 28435556

13. Saco M, Howe N, et al. Comparing the efficacies of alginate, foam, hydrocolloid, hydrofiber, and hydrogel dressings in the management of diabetic foot ulcers and venous leg ulcers: a systematic review and meta-analysis examining how to dress for success. Dermatol Online J. 2016; 22(8).

14. Liberati A, Altman DG, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med. 2009; 6 (7):e1000100. https://doi.org/10.1371/journal.pmed.1000100 PMID: 19621070

15. Husereau D, Drummond M, et al. Consolidated Health Economic Evaluation Reporting Standards (CHEERS)—explanation and elaboration: A report of the ISPOR health economic evaluation publication guidelines good reporting practices task force. Value Health. 2013; 16(2):231–50. https://doi.org/10.1016/j.jval.2013.02.002 PMID: 23538175

16. di Palo Michele T. Rating satisfaction research: Is it poor, fair, good, very good, or excellent? Arthritis Rheum. 1997; 10(6):422–30.

17. Hope SF, Webster J, et al. A systematic review of economic evaluations of population-based sodium reduction interventions. PLoS One. 2017; 12(3).

18. Langer A. A framework for assessing Health Economic Evaluation (HEE) quality appraisal instruments. BMC Health Serv Res. 2012; 12:253-. https://doi.org/10.1186/1472-6963-12-253 PMID: 22894708

19. Sommariva S, Tarricone R, et al. Prognostic value of the cell cycle progression score in patients with prostate cancer: A systematic review and meta-analysis. Eur Urol. 2016; 69(1):107–15. https://doi.org/10.1016/j.euro.2014.11.038 PMID: 25481455

20. Cohen J. A coefficient of agreement for nominal scales. Educ Psychol Meas. 1960; 20:37–46.

21. Apelqvist J, Ragnarson Tennvall G. Cavity foot ulcers in diabetic patients: A comparative study of cadexomer iodine ointment and standard treatment. An economic analysis alongside a clinical trial. Acta Derm Venereol 1996; 76(3):231–5. https://doi.org/10.2340/00015555-76231325 PMID: 8803077

22. Habacher W, Rakovac I, et al. A model to analyse costs and benefit of intensified diabetic foot care in Austria. J Eval Clin Pract. 2007; 13(6):906–12. https://doi.org/10.1111/j.1365-2753.2006.00770.x PMID: 18070261

23. Chow I, Lemos EV, et al. Pharmacoeconomic analysis of guidelines for treating mild diabetic foot infections: A decision-tree model for Canada. Can J Hosp Pharm. 2008; 61(6):412–21.

24. Green W, Taylor M. Cost-effectiveness analysis of d-Nav for people with diabetes at high risk of neuropathic foot ulcers. Diabetes Ther. 2016; 7(3):511–25. https://doi.org/10.1007/s13300-016-0183-x PMID: 27402392

25. Onchari Divinah N, Simon JM, et al. Appropriate empirical management of microbial infections in a tertiary care hospital: A cost-effectiveness approach. Asian J Pharm Clin Res. 2018; 11(2):124–7.

26. Jansen JP, Kumar R, et al. Accounting for the development of antibacterial resistance in the cost effectiveness of ertapenem versus piperacillin/tazobactam in the treatment of diabetic foot infections in the UK. Pharmacoconomics. 2009; 27(12):1045–56. https://doi.org/10.2165/11310080-000000000-00000 PMID: 19908928

27. Eckman MH, Greenfield S, et al. Foot infections in diabetic patients. Decision and cost-effectiveness analyses. JAMA. 1995; 273(9):712–20. PMID: 7853629

28. Kirsner R. Clinical evidence for and cost-effectiveness of advanced cellular tissue products for the treatment of diabetic foot ulcers. Am J Manag Care. 2018; 24(14 Spec No.):SP607–SP608. PMID: 30620545

29. Shannon R. A cost-utility evaluation of best practice implementation of leg and foot ulcer care in the Ontario community. Wound Care Canada. 2007; 5(1):SS3.
30. Balderas-Pena LM, Sat-Munoz D, et al. Descriptive, longitudinal study results applied to statistical models to assess the impact of early microbiological cultures on the economic burden of treatment for infected diabetic foot ulcers at a mexican public health facility. Ostomy Wound Manage. 2016; 62 (12):14–28. PMID: 28054923

31. Gonen MS, Çakir M, et al. The problems and cost-effectiveness analysis of diabetic foot infections. Turk J Endocrinol Metab. 2012; 16(1):10–3.

32. Goulionis JE, Vozikis A, et al. On the decision rules of cost-effective treatment for patients with diabetic foot syndrome. Clinicoecon Outcomes Res 2010; 2:121–6. https://doi.org/10.2147/CEOR.S11981 PMID: 21935321

33. Guest JF, Fuller GW, et al. Diabetic foot ulcer management in clinical practice in the UK: Costs and outcomes. Int Wound J. 2018; 15(1):43–52. https://doi.org/10.1111/iwj.12816 PMID: 29243399

34. Jeffcoate W, Game F, et al. Evaluation of the effectiveness and cost-effectiveness of lightweight fibre-glass heel casts in the management of ulcers of the heel in diabetics: A randomised controlled trial. Health Technol Assess. 2017; 21(34). https://doi.org/10.3310/hta21340 PMID: 28644115

35. Jeffcoate W, Price P, et al. Randomised controlled trial of the use of three dressings in the management of chronic ulceration of the foot in diabetics. Health Technol Assess. 2009; 13(37):1–110.

36. Malone M, West D, et al. Outcomes and cost minimisation associated with outpatient parenteral antimicrobial therapy (OPAT) for foot infections in people with diabetes. Diabetes Metab Res Rev. 2015; 31 (6):638–45. https://doi.org/10.1002/dmrr.2651 PMID: 25850572

37. McMillan G, Glover M. The clinical and economic potential of hyperbaric oxygen therapy in the treatment of diabetic ulceration and other conditions. Int J Low Extrem Wounds. 2007; 6(3):130–8. https://doi.org/10.1177/1534734607034626 PMID: 17909170

38. Nussbaum SR, Carter MJ, et al. An economic evaluation of the impact, cost, and medicare policy implications of chronic nonhealing wounds. Value Health. 2018; 21(1):27–32. https://doi.org/10.1016/j.jval.2017.07.007 PMID: 29309397

39. Ragnarson Tennvall G, Apelqvist J, et al. Costs of deep foot infections in patients with Diabetes Mellitus. Pharmacoeconomics. 2000; 18(3):225–38. https://doi.org/10.2165/00019053-200018030-00003 PMID: 11147390

40. Redekop WK, Stolk EA, et al. Diabetic foot ulcers and amputations: estimates of health utility for use in cost-effectiveness analyses of new treatments. Diabetes Metab. 2004; 30(6):549–56. https://doi.org/10.1016/s1262-3636(07)70154-4 PMID: 15671925

41. Cárdenas M AJ M, et al. The cost of illness attributable to diabetic foot and cost-effectiveness of secondary prevention in Peru. BMC Health Serv Res. 2015; 15.

42. Cheng Q, Lazzarini PA, et al. A cost-effectiveness analysis of optimal care for diabetic foot ulcers in Australia. Int Wound J. 2017; 14(4):616–28. https://doi.org/10.1111/iwj.12653 PMID: 27489228

43. Chuck AW, Hailey D, et al. Cost-effectiveness and budget impact of adjunctive hyperbaric oxygen therapy for diabetic foot ulcers. Int J Technol Assess Health Care. 2008; 24(2):178–83. https://doi.org/10.1017/S0266462308020252 PMID: 18400121

44. Dougherty EJ. An evidence-based model comparing the cost-effectiveness of platelet-rich plasma gel to alternative therapies for patients with nonhealing diabetic foot ulcers. Adv Skin Wound Care. 2008; 21(12):568–75. https://doi.org/10.1097/01.ASW.0000323589.27605.71 PMID: 19065083

45. Flack S, Apelqvist J, et al. An economic evaluation of VAC therapy compared with wound dressings in the treatment of diabetic foot ulcers. J Wound Care. 2008; 17(2):71–8. https://doi.org/10.12968/jowc.2008.17.2.28181 PMID: 18389832

46. Gilligan AM, Waycaster CR, et al. Wound closure in patients with DFU: a cost-effectiveness analysis of two cellular/tissue-derived products. J Wound Care. 2015; 24(3):149–56. https://doi.org/10.12968/jowc.2015.24.3.149 PMID: 25764960

47. Guest JF, Singh H, et al. Potential cost-effectiveness of using a collagen-containing dressing in managing diabetic foot ulcers in the UK. J Wound Care. 2018; 27(3):136–44. https://doi.org/10.12968/jowc.2018.27.3.136 PMID: 29509110

48. Guo S, Counte MA, et al. Cost-effectiveness of adjunctive hyperbaric oxygen in the treatment of diabetic ulcers. In J Technol Assess Health Care. 2004; 19(4):731–7.

49. Lobmann R, Augustin M, et al. Cost-effectiveness of TLC-sucros e octasulfate versus control dressings in the treatment of diabetic foot ulcers. J Wound Care. 2019; 28(12):808–16. https://doi.org/10.12968/jowc.2019.28.12.808 PMID: 31825772

50. McKinnon PS, Paladino JA, et al. Cost-effectiveness of ampicillin/subbactam versus imipenem/cilastatin in the treatment of limb-threatening foot infections in diabetic patients. Clin Infect Dis. 1997; 24(1):57–63. https://doi.org/10.1093/clinids/24.1.57 PMID: 8994756
51. Ortegon MM, Redekop WK, et al. Cost-effectiveness of prevention and treatment of the diabetic foot: a Markov analysis. Diabetes Care. 2004; 27(4):901–7. https://doi.org/10.2337/diacare.27.4.901 PMID: 15047646

52. Persson U, Willis M, et al. The cost-effectiveness of treating diabetic lower extremity ulcers with becaplermin (Regranex): a core model with an application using Swedish cost data. Value Health. 2000; 3 Suppl 1:39–46.

53. Ragnarson Tennvall G, Apelqvist J. Prevention of diabetes-related foot ulcers and amputations: a cost-utility analysis based on Markov model simulations. Diabetologia. 2001; 44(11):2077–87. https://doi.org/10.1007/s001250100013 PMID: 11719840

54. Redekop WK, McDonnell J, et al. The cost effectiveness of Apligraf treatment of diabetic foot ulcers. Pharmacoeconomics. 2003; 21(16):1171–83. https://doi.org/10.2165/00019053-200321160-00003 PMID: 14594438

55. Romero Prada M, Roa C, et al. Cost-effectiveness analysis of the human recombinant epidermal growth factor in the management of patients with diabetic foot ulcers. Diabet Foot Ankle. 2018; 9(1):1480249. https://doi.org/10.1080/2000625X.2018.1480249 PMID: 29963295

56. Tesar T, Szilberhorn L, et al. Cost-utility analysis of Heberprot-P as an add-on therapy to good wound care for patients in Slovakia with advanced diabetic foot ulcer. Front Pharmacol. 2017; 8(946).

57. Tice AD, Turpin RS, et al. Comparative costs of ertapenem and piperacillin-tazobactam in the treatment of diabetic foot infections. Am J Health Syst Pharm. 2007; 64(10):1080–6. https://doi.org/10.1093/ajhp/64.10.1080 PMID: 17494908

58. Waycaster CR, Gilligan AM, et al. Cost-effectiveness of becaplermin gel on diabetic foot ulcer healing. J Am Podiat Med Assn. 2016; 106(4):273–82.

59. Wu B, Wan X, et al. Cost-effectiveness of prevention and management of diabetic foot ulcer and amputation in a health resource-limited setting. J Diabetes. 2018; 10(4):320–7. https://doi.org/10.1111/1753-0407.12612 PMID: 28976723

60. Lavery LA, Davis KE, et al. WHS guidelines update: Diabetic foot ulcer treatment guidelines. Wound Rep and Reg. 2016; 24(1):112–26.